Please select the option that best describes you:
How would you treat an LGL leukemia patient who has been refractory to treatments with cyclosporine, MTX, and cyclophosphamide?
The patient also has transfusion-dependent anemia secondary to the LGL leukemia.
Answer from: Medical Oncologist at Community Practice
In my experience, true refractoriness to methotrexate and cyclophosphamide is unusual in LGL. What is more usual is that patients take a long time to respond and I usually don’t change therapy before a full 6 months trial of either agents. That is also what the published data suggests. In the ...
Sign in or Register to read more